Coferon Inc., a biotechnology company, announced a $12 million Series B financing round led by new venture investors. Dr. Colin Goddard was appointed as Chairman and CEO. The company focuses on using proprietary bioorthogonal linker chemistry for drug development, targeting epigenetic regulatory proteins and anti-infectives.
documents/EFTA01092527.pdf
{}